Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$299
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
Cagrilintide is a long-acting amylin receptor analog structurally derived from human amylin (IAPP), with proline substitutions at positions 25 and 28 and a C18 fatty acid chain to prevent β-sheet aggregation and extend circulating half-life.
Research panels frequently pair cagrilintide with GLP-1R agonists to examine whether AMY receptor co-stimulation modifies incretin-pathway outputs. Its stability advantage over native IAPP also makes it useful as a non-aggregating amylin reference in fibrillation inhibition screens.
Browse Inventory
In research literature, Cagrilintide is generally treated as a long-acting amylin receptor analog structurally derived from human amylin (IAPP), with proline substitutions at positions 25 and 28 and a C18 fatty acid chain to prevent β-sheet aggregation and extend circulating half-life. Amylin receptors are obligate heterodimers of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMP1-3), generating AMY1, AMY2, and AMY3 subtypes with distinct ligand preferences. Cagrilintide binding triggers Gs-mediated cAMP accumulation and, depending on receptor subtype, Gq-linked IP3/DAG signalling, making subtype selectivity a relevant experimental variable. Wild-type human amylin (hIAPP) fibrillises rapidly in vitro at physiological concentrations — the proline substitutions in cagrilintide prevent β-sheet nucleation, providing a stable monomeric comparator for aggregation kinetics studies.
Research panels frequently pair cagrilintide with GLP-1R agonists to examine whether AMY receptor co-stimulation modifies incretin-pathway outputs. Its stability advantage over native IAPP also makes it useful as a non-aggregating amylin reference in fibrillation inhibition screens. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Cagrilintide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for Cagrilintide should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for Cagrilintide is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare Cagrilintide with Cagrilintide + Semaglutide, Klow, and BPC-157 + TB-500, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 2 labelled variants: 5mg and 10mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
Cagrilintide is generally discussed as a long-acting amylin receptor analog structurally derived from human amylin (IAPP), with proline substitutions at positions 25 and 28 and a C18 fatty acid chain to prevent β-sheet aggregation and extend circulating half-life. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
